Market closed
Syndax Pharmaceuticals/$SNDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Syndax Pharmaceuticals
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Ticker
$SNDX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
270
Website
SNDX Metrics
BasicAdvanced
$1.2B
-
-$3.72
0.92
-
Price and volume
Market cap
$1.2B
Beta
0.92
52-week high
$25.07
52-week low
$9.66
Average daily volume
1.8M
Financial strength
Current ratio
5.824
Quick ratio
5.763
Long term debt to equity
115.625
Total debt to equity
119.997
Interest coverage (TTM)
-68.91%
Management effectiveness
Return on assets (TTM)
-31.74%
Return on equity (TTM)
-75.69%
Valuation
Price to revenue (TTM)
49.645
Price to book
4.08
Price to tangible book (TTM)
4.08
Price to free cash flow (TTM)
-4.276
Growth
Earnings per share change (TTM)
24.93%
3-year revenue growth (CAGR)
-44.66%
3-year earnings per share growth (CAGR)
100.77%
What the Analysts think about SNDX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Syndax Pharmaceuticals stock.
SNDX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SNDX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SNDX News
AllArticlesVideos
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire·1 day ago
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
GlobeNewsWire·6 days ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Syndax Pharmaceuticals stock?
Syndax Pharmaceuticals (SNDX) has a market cap of $1.2B as of May 04, 2025.
What is the P/E ratio for Syndax Pharmaceuticals stock?
The price to earnings (P/E) ratio for Syndax Pharmaceuticals (SNDX) stock is 0 as of May 04, 2025.
Does Syndax Pharmaceuticals stock pay dividends?
No, Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders as of May 04, 2025.
When is the next Syndax Pharmaceuticals dividend payment date?
Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.